Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance

Department of Cardiology, Pulmonology, Angiology, Heinrich-Heine-University, Dusseldorf, Germany.

OBJECTIVES: The aim of this study was to investigate whether intracoronary infusion of dipyridamole represents a suitable tool for preventing deterioration of left ventricular performance and hemodynamic function during percutaneous transluminal coronary angioplasty (PTCA). BACKGROUND: Coronary angioplasty represents a suitable model for establishing myocardial ischemia in humans. Balloon inflation is usually accompanied by significant deterioration in left ventricular systolic and diastolic properties. A brief episode of ischemia followed by reperfusion, termed preconditioning, has been identified as a mechanism for rendering the myocardium more resistant to ischemia. Adenosine is considered an important mediator of preconditioning. Dipyridamole is an important drug that interferes with myocardial adenosine metabolism by inhibiting its cellular reuptake. METHODS: In 20 patients undergoing elective coronary angioplasty of a major vessel, assessment of angiographic left ventricular performance and hemodynamic variables was performed before, during and after PTCA. Patients were randomly allocated to pretreatment with intracoronary infusion of dipyridamole before percutaneous transluminal coronary angioplasty (10 patients) or conventional pretreatment without dipyridamole (10 patients). RESULTS: Dipyridamole pretreatment resulted in significant preservation of systolic and diastolic left ventricular performance during percutaneous transluminal coronary angioplasty, as documented by an unaffected global ejection fraction (vs. a deterioration of 29.2% with conventional pretreatment, p < 0.01) and an increment in diastolic stiffness of only 12.7% (vs. an increment of 57.3% with conventional pretreatment, p < 0.01). Apart from one instance of coronary steal phenomenon, no significant side effects of dipyridamole infusion could be detected. CONCLUSIONS: It is concluded that intracoronary application of dipyridamole may result in the induction of myocardial preconditioning by improving systolic and diastolic ventricular performance during percutaneous transluminal coronary angioplasty, thereby potentially reducing the risk of the angioplasty procedure.

This article has been cited by other articles:

				Y. Ye, Y. Lin, R. Perez-Polo, M.-H. Huang, M. G. Hughes, D. J. McAdoo, S. Manickavasagam, B. F. Uretsky, and Y. Birnbaum Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H813 - H818. [Abstract] [Full Text] [PDF]

				T B Lindhardt, N Gadsboll, H Kelbaek, K Saunamaki, J K Madsen, P Clemmensen, B Hesse, and S Haunso Pharmacological modulation of the ATP sensitive potassium channels during repeated coronary occlusions: no effect on myocardial ischaemia or function Heart, April 1, 2004; 90(4): 425 - 430. [Abstract] [Full Text] [PDF]

				A. Gamboa, A. C. Ertl, F. Costa, G. Farley, M. L. Manier, D. L. Hachey, A. Diedrich, and I. Biaggioni Blockade of Nucleoside Transport Is Required for Delivery of Intraarterial Adenosine Into the Interstitium: Relevance to Therapeutic Preconditioning in Humans Circulation, November 25, 2003; 108(21): 2631 - 2635. [Abstract] [Full Text] [PDF]

				W. K. Laskey and D. Beach Frequency and clinical significance of ischemic preconditioning during percutaneous coronary intervention J. Am. Coll. Cardiol., September 17, 2003; 42(6): 998 - 1003. [Abstract] [Full Text] [PDF]

				J. Vinten-Johansen, Z.-Q. Zhao, J. S. Corvera, C. D. Morris, J. M. Budde, V. H. Thourani, and R. A. Guyton Adenosine in myocardial protection in on-pump and off-pump cardiac surgery Ann. Thorac. Surg., February 1, 2003; 75(2): S691 - 699. [Abstract] [Full Text] [PDF]

				E. Picano and on behalf of the PISA study group Dipyridamole in chronic stable angina pectoris. A randomized, double blind, placebo-controlled, parallel group study Eur. Heart J., October 1, 2001; 22(19): 1785 - 1793. [Abstract] [PDF]

				K. Mubagwa and W. Flameng Adenosine, adenosine receptors and myocardial protection: An updated overview Cardiovasc Res, October 1, 2001; 52(1): 25 - 39. [Abstract] [Full Text] [PDF]

				M P Heintzen, U E Heidland, W J Klimek, M Leschke, M Kelm, B Schwartzkopff, E G Vester, C J Michel, and B E Strauer Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial Heart, May 1, 2000; 83(5): 551 - 556. [Abstract] [Full Text]

				Y. Yoshida, M. Hirai, T. Yamada, Y. Tsuji, T. Kondo, Y. Inden, M. Akahoshi, Y. Murakami, M. Tsuda, N. Tsuboi, et al. Antiarrhythmic Efficacy of Dipyridamole in Treatment of Reperfusion Arrhythmias : Evidence for cAMP-Mediated Triggered Activity as a Mechanism Responsible for Reperfusion Arrhythmias Circulation, February 15, 2000; 101(6): 624 - 630. [Abstract] [Full Text] [PDF]

				S. Tommasi, E. Carluccio, M. Bentivoglio, L. Corea, and E. Picano Low-dose dipyridamole infusion acutely increases exercise capacity in angina pectoris: A double-blind, placebo controlled crossover stress echocardiographic study J. Am. Coll. Cardiol., January 1, 2000; 35(1): 83 - 88. [Abstract] [Full Text] [PDF]

				V. M. Figueredo, I. Diamond, H.-Z. Zhou, and S. A. Camacho Chronic dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, November 1, 1999; 277(5): H2091 - H2097. [Abstract] [Full Text] [PDF]

				W. K. Laskey Beneficial Impact of Preconditioning During PTCA on Creatine Kinase Release Circulation, April 27, 1999; 99(16): 2085 - 2089. [Abstract] [Full Text] [PDF]